Newly Approved Cell Therapy For Advanced Melanoma, Amtagvi, Is A Potential Breakthrough
A confirmatory Phase 3 trial is ongoing to verify Amtagvi ’s clinical benefit in advanced melanoma patients. If confirmed, Amtagvi will be an important breakthrough. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 4, 2024 Category: Pharmaceuticals Authors: Joshua Cohen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Kimmtrak Tebentafusp Sales Increase By 64% In 2023
In the battle against melanoma, Kimmtrak has emerged as a groundbreaking treatment that offers an innovative approach of treatment with significant commercial potential. Although Kimmtrak is currently only approved for the treatment of uveal melanoma, clinical trials are being conducted to…#tebentafusp #immunocore (Source: Reuters: Health)
Source: Reuters: Health - February 29, 2024 Category: Consumer Health News Source Type: news
What ’s The Incidence Rate of a Second Primary Melanoma? What ’s The Incidence Rate of a Second Primary Melanoma?
The findings may have potential implications for more personalized surveillance of patients with melanoma, the authors said.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 29, 2024 Category: Internal Medicine Tags: Dermatology Source Type: news
Delayed Melanoma Care During Pandemic Proved Costly
TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs, according to a study published online Feb. 16 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2024 Category: Pharmaceuticals Source Type: news
FDA Approves 1st T-Cell Therapy For Melanoma
Authored by Amie Dahnke via The Epoch Times (emphasis ours), Melanoma cancer patients with solid tumors can turn to a new treatment thanks to the U.S. Food and Drug Administration’s (FDA) approval of a new class of immunotherapy. The new treatment may…#fda #amiedahnke #epochtimes #melanoma #amtagvi #samantharguild #aim #melanomafoundation #petermarks #hispanic (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2024 Category: Consumer Health News Source Type: news
News at a glance: Protecting a queen, cell therapy for solid tumors, and a UV telescope
CONSERVATION
U.S. protects iconic marine snail
The queen conch, a large marine snail known for its showy shell and delectable flesh, has been added to the U.S. government’s list of species threatened with extinction. Scientists at the National Oceanic and Atmospheric Administration (NOAA) said the species (
Strombus gigas
, pictured), which is native to the Caribbean region and grows up to 35 centimeters long, needs protection because populations are sparse, scattered, and heavily overfished. NOAA’s listing decision, issued on 14 February, has no immediate impact but authorizes the age...
Source: ScienceNOW - February 22, 2024 Category: Science Source Type: news
Iovance stock soars on FDA approval of its melanoma gene therapy
Iovance has its gene therapy manufacturing plant at the Philadelphia Navy Yard. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 20, 2024 Category: Biotechnology Authors: John George Source Type: news
Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first cellular therapy approved to treat this form of solid tumor cancer. " The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 20, 2024 Category: Pharmaceuticals Source Type: news
FDA Grants Accelerated Approval for Amtagvi (lifileucel) for the Treatment of Advanced Melanoma
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2024 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Treatment for Advanced Melanoma, Amtagvi
MONDAY, Feb. 19, 2024 -- The U.S. Food and Drug Administration has approved a novel treatment for advanced melanoma, the most deadly form of skin cancer.
Amtagvi, made by Iovance Biotherapeutics Inc., becomes the first cellular therapy approved to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 19, 2024 Category: General Medicine Source Type: news
Miami Cancer Institute to host second Precision Oncology Symposium to advance cancer treatment
Miami Cancer Institute, part of Baptist Health South Florida, will host its second annual Precision Oncology Symposium from April 19-20, according to the symposium organizers. This one-and-a-half-day symposium, to be held in Miami, has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of solid tumors — including lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas, and brain… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 19, 2024 Category: Biotechnology Authors: Baptist Health Source Type: news
FDA approves first cell therapy to treat aggressive forms of melanoma
Amtagvi is intended to help patients with melanoma that cannot be removed with surgery or has spread to other parts of the body. (Source: NPR Health and Science)
Source: NPR Health and Science - February 17, 2024 Category: Consumer Health News Authors: Juliana Kim Source Type: news
In'major milestone,' FDA approves first cell therapy for solid tumors
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from…#iovance #allisonbetofwarner #stanforduniversity #betofwarner (Source: Reuters: Health)
Source: Reuters: Health - February 17, 2024 Category: Consumer Health News Source Type: news
Inaugural Award Poised to Advance Treatment Options for Uveal Melanoma Patients
CURE OM Team Award Earmarks a Significant Milestone for the Uveal Melanoma Population WASHINGTON , Feb. 16, 2024 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) recently announced the winners of the inaugural CURE OM Options Bring Hope Team Science Award: Bruce Ksander, PhD... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 17, 2024 Category: Pharmaceuticals Tags: AWD Source Type: news
